Ten-year follow-up of renal adenomatosis with magnetic resonance imaging: a case report

Yi-Chen Chou1, Wen-Ying Lee2,3, Steven K. Huang4, Reng-Hong Wu1 and Yu-Ting Kuo1,5,6*

Abstract

**Background:** Renal adenomatosis is a rare disease that presents as multiple papillary adenomas in the bilateral kidneys. Moreover, papillary adenoma is considered a precursor to papillary renal cell carcinoma. Therefore, patients with renal adenomatosis may have a higher risk of developing malignancy than patients without this benign condition.

**Case presentation:** We present the case of a 62-year-old Asian woman with a past history of papillary thyroid cancer. She underwent contrast-enhanced magnetic resonance imaging of the abdomen to screen for metastasis in 2010 and was followed up with computed tomography or magnetic resonance imaging annually. She was found to have a right renal tumor on computed tomography and underwent partial nephrectomy. The pathological diagnosis of the right renal tumor was angiomyolipoma. Renal adenomatosis was also histologically confirmed in the renal parenchyma adjacent to the angiomyolipoma. In this case report, we demonstrate the natural course of renal adenomatosis over 10 years using imaging studies. The benign tumors gradually progressed during the follow-up period. Larger tumor sizes and more hypoenhanced nodules in the bilateral kidneys were observed on follow-up computed tomography and magnetic resonance imaging.

**Conclusions:** Due to its malignant potential, the clinical course of renal adenomatosis must be monitored. We present the natural course of renal adenomatosis with magnetic resonance imaging during a 10-year follow-up period.

**Keywords:** Renal adenomatosis, Renal cell carcinoma, Magnetic resonance imaging, Case report

Background

Renal papillary adenoma is a benign epithelial tumor of the kidney with the following pathological features: unencapsulated tumor with papillary, tubulopapillary, or tubular architecture, low nuclear-to-cytoplasmic ratio, and diameter less than 15 mm. Renal adenomatosis is characterized by multiple (usually more than five) adenomas in one kidney [1]. Syrjanen et al. reported the first case of renal adenomatosis in 1978 [2], and since then, only a few cases have been reported. The incidence of papillary adenoma increases with age. Patients with renal adenomatosis might be diagnosed with glomerulosclerosis or chronic renal damage [3–5]. Papillary adenoma is considered a precursor lesion of papillary renal cell carcinoma because it shares similar immunohistochemical profiles and genetics, as reported in recent studies [6–8]. There is no unanimously accepted standard treatment for this disease. We report a particular case of renal adenomatosis with a series of imaging studies over a 10-year follow-up period.

**Case presentation**

A 62-year-old Asian woman with hypertension was under medical control with β-adrenergic blocking agents and calcium channel blockers for approximately 10 years. Hypertension was also noted in her family history. She underwent a thyroidectomy for treatment of papillary thyroid cancer in 2004. After the operation, she regularly took levothyroxine to maintain her thyroid hormone levels.
She denied smoking or consuming alcohol. She had a daughter and entered menopausal status when she was 49 years old. She underwent screening with contrast-enhanced magnetic resonance imaging (MRI) of the abdomen in 2010 (Fig. 1). This MRI study revealed multiple nodules in the bilateral renal cortices, with mild hypointensity on T2-weighted (T2W) images and isointensity of the adjacent renal cortex on T1-weighted (T1W) images. Diffusion restriction on the apparent diffusion coefficient (ADC) map and hyperintensity on diffusion-weighted images (DWIs) were also seen. Relatively poor enhancement on contrast-enhanced T1W images was observed.

Ten years later, follow-up MRI findings in 2020 (Fig. 2) revealed a higher tumor number and larger lesions than seen in previous studies in 2010. In 2010, most of the tumors were smaller than 10 mm, while in 2020, several tumors were larger than 10 mm. Otherwise, these renal nodules presented with imaging features similar to those observed 10 years earlier. Biological markers of kidney function (such as serum creatinine, blood urea nitrogen, and urine analysis) were within normal limits (Tables 1 and 2). However, the tumor marker CA 19-9 level increased progressively over the 10-year period (from 228.2 U/mL in 2010 to 654.9 U/mL in 2020), while no apparent tumors were noted in the hepatobiliary system or pancreas.

A renal tumor was noted in the right kidney on a follow-up contrast-enhanced computed tomography (CT) scan in 2018 (Fig. 3), which showed an enhancing pattern that differed from that of the other renal nodules. In addition, there were multiple hypoenhanced nodules in both kidneys in the parenchymal phase. Because the possibility of a malignant tumor could not be excluded, the patient subsequently underwent right partial nephrectomy for tumor resection in November 2018. During admission, there were no abnormal findings on physical or neurological examinations (her sclera was anicteric, her conjunctiva was pink, no neck mass, clear breathing sounds, no heart murmur, soft abdominal wall without striae, normal muscle power, and deep tendon reflex), and her vital signs were also stable (Table 3). She continued taking antihypertensive medication and levothyroxine during her hospital stay. The renal tumor was a well-defined tumor with a predominant myomatous element admixing with tortuous vessels and some adipose elements, which are pathological characteristic features of epithelioid angiomyolipoma. Furthermore, some large and unusual hyperchromatic nuclei without evident mitotic activity were also noted. Immunohistochemically, the tumor cells were positive for melan-A protein and smooth muscle actin staining (Fig. 4a, b).

Furthermore, in addition to angiomyolipoma, there were multiple small renal tumors in the adjacent renal parenchyma, which were considered to be papillary adenomas (Fig. 4c). Pathological analysis of peritumoral tissue from the partial nephrectomy specimen showed multiple unencapsulated proliferative epithelial nodules with papillary, tubular, or tubulopapillary configurations (Fig. 4d). The tumor cells had low-grade nuclei. The tumors were as large as 1 cm. Immunohistochemically,
the tumor cells were positive for cytokeratin 7 (CK7) (Fig. 4e) and focally positive for α-methylacyl-coenzyme A racemase (AMACR, also called p504s) but negative for thyroid transcription factor-1. Therefore, we excluded the possibility of metastasis with a thyroid origin. The multiple tumors showed a morphology and immunophenotype similar to those of papillary renal cell carcinoma; however, the size of these papillary tumors did not exceed 15 mm. Therefore, a diagnosis of renal adenomatosis was established.

Due to the malignant potential of renal adenomatosis, tumor biopsy was performed under ultrasound guidance in September 2020. The pathological analysis revealed no malignant features and no increase in the nuclear-to-cytoplasmic ratio.

**Discussion**

The patient was a 62-year-old female with hypertension and papillary thyroid cancer. She was incidentally found to have renal adenomatosis and underwent MRI follow-up for 10 years. For the first time, we demonstrate the natural course of renal adenomatosis using MRI.

Renal papillary adenoma is a benign tumor that is reported in 7% of kidney resections performed for other tumors, most commonly for renal cell carcinoma, showing an incidence of 19% in an autopsy study [3, 7]. Renal adenomatosis is characterized by five or more

---

**Table 1** Blood tests in 2010, 2018, and 2020

|               | 2010  | 2018  | 2020  | Reference |
|---------------|-------|-------|-------|-----------|
| CBC           |       |       |       |           |
| WBC (x 10^6/µL) | 5.3   | 6.0   | 7.3   | 3.2–9.2   |
| RBC (x 10^5/µL) | 3.83  | 3.64  | 4.00  | 3.7–4.9   |
| Platelets (x 10^9/µL) | 163   | 192   | 187   | 150–400   |
| GOT (IU/L)    | 24    | 20    | 22    | 5–34      |
| GPT (IU/L)    | 27    | 13    | 19    | 2–40      |
| BUN (mg/dL)   | 19    | 17    | 20    | 6–20      |
| Creatinine (mg/dL) | 0.6   | 0.85  | 0.75  | 0.57–1.11 |
| CA 19-9 (U/mL) | 187   | 502   | 798   | <37       |
| T4 (ng/dL)    | 1.28  | 6.4   | 7.1   | 4.5–12.5  |
| TSH (µIU/mL)  | 0.12  | 5.89  | 0.51  | 0.25–4.0  |

CBC: complete blood count, WBC: white blood cell count, RBC: red blood cell count, GOT: glutamic oxaloacetic transaminase, GPT: glutamic pyruvic transaminase, BUN: blood urea nitrogen, CA 19-9: carbohydrate antigen 19-9, TSH: thyroid-stimulating hormone.

**Table 2** Urinary analysis in 2010, 2018, and 2020

|               | 2010  | 2018  | 2020  | Reference |
|---------------|-------|-------|-------|-----------|
| Appearance    | Clear | Clear | Clear | Clear     |
| Sediment-WBC (HPF) | <1    | <1    | 1–4   | 0–5       |
| Sediment-RBC (HPF) | <1    | <1    | 1–4   | 0–2       |
| Sediment-Bacilli (HPF) | –     | –     | –     | –         |
| Leukocyte esterase | –     | –     | +/–   | –         |

WBC: white blood cell count, RBC: red blood cell count, HPF: high-power field.
adenomas in one kidney. The prevalence of renal adenomatosis has not been previously reported. The first case of renal adenomatosis was reported by Syrjanen in 1979 [2], and only 16 cases of renal adenomatosis have been reported to date. The incidence of papillary adenoma increases with age, glomerulosclerosis, or chronic renal damage [3–5]. According to Kim et al. [9], renal papillary adenoma can also be observed in patients with acquired cystic disease or hereditary papillary renal cancer.

Pathologically, renal papillary adenoma and papillary renal cell carcinoma can be divided into four subgroups (types A, B, C, and D) and two subgroups (types 1 and 2), respectively. Type A and D renal papillary adenomas have similar histology and genetic features to type 1 and 2 papillary renal cell carcinoma [3]. These findings are consistent with those reported in a study conducted by Brunelli et al. They found similar chromosomal changes between renal papillary adenoma and papillary renal cell carcinoma [7, 8]. Similar immunohistochemical markers (CK7 and AMACR) have also been reported between papillary adenoma and papillary renal cell carcinoma [7, 9, 10]. In this case, we also observed positive immunohistochemical staining for CK7 and AMACR.

Renal adenomatosis is rarely diagnosed preoperatively, not only because of its low prevalence but also because of radiologists’ unfamiliarity with its imaging features. To the best of our knowledge, this is the first report to demonstrate the natural course of renal adenomatosis with a series of imaging studies over a 10-year follow-up period.

Some experts consider that papillary adenoma and papillary renal cell carcinoma have a similar disease course. In the 2016 World Health Organization (WHO) classification system, the threshold for papillary renal adenoma is 15 mm in size, while the corresponding threshold was 5 mm in the 2004 WHO classification system. The reason for this is the low probability of metastasis when a renal tumor is smaller than 20 mm [11]. Additionally, Thompson et al.
reported that the risk of metastasis may be negligible if the tumor is smaller than 30 mm after the patient undergoes nephrectomy [12]. Renal papillary adenoma certainly has malignant potential. However, apart from the size criterion, how to determine whether an adenoma will progress to papillary renal cell carcinoma...
remains unknown. In the present case, the adenoma showed slow progression over 10 years without evidence of metastasis. Currently, there is no definite treatment for renal adenomatosis. The benefits of prophylactic surgery, such as bilateral nephrectomy, remain unclear.

Several other diseases need to be differentiated from renal adenomatosis on imaging studies because they also demonstrate small hypoenhanced nodules in bilateral renal parenchyma. For example, renal tuberculosis should be considered. Tuberculosis usually initially spreads in the medullary portion of the kidney and is often associated with collecting system diseases, such as infundibular stenosis with caliectasis, ureteral stricture, or ureteral wall thickening. Some cortical granulomas coalesce with calcifications. In immunocompromised patients, miliary tuberculosis may be observed, appearing as multiple hypoenhanced nodules in the bilateral kidneys that are usually smaller than 3 mm in diameter and in the renal cortex [13]. On enhanced CT images, cortical granulomas are hypotenuated relative to the adjacent renal cortex [14].

Renal lymphoma can present as a solitary renal nodule, multiple bilateral renal nodules, soft tissue in the perinephric space, a direct extension from retroperitoneal adenopathy, or infiltration lesions in the bilateral kidneys [15]. The size of lymphomas usually varies, but lymphomas larger than 15 mm in diameter are more common. On CT images, renal lymphoma is usually more hypoenhanced than the adjacent renal cortex but is gradually enhanced in the corticomedullary phase. On MRI, renal lymphoma can be hypointense on T1W images and slightly more hypo- or isointense than the adjacent normal renal cortex on T2W images, with gradual contrast enhancement on postcontrast T1W images. Lymphomas usually show diffusion restriction on DWI and ADC maps. Renal lymphoma usually shows marked fluorodeoxyglucose (FDG) uptake on positron emission tomography images [16].

Immunoglobulin G4 (IgG4)-related disease is a systemic disease, and the most commonly affected organ is the pancreas, resulting in IgG4-related autoimmune pancreatitis. Isolated IgG4-related renal disease is rare; only 3% of patients have renal lesions without involvement of other organs [17]. Five IgG4-related renal disease patterns have been described, and bilateral round- or wedge-shaped peripheral cortical lesions are the most common type [18]. On CT images, the bilateral round renal nodules in the peripheral cortex show similar attenuation to the renal parenchyma and hypotenuation relative to the renal parenchyma on enhanced images. IgG4-related renal nodules are hypointense on T1W and T2W MR images and mildly enhanced on postcontrast T1W MR images [19].

Conclusions

We report a case with a series of follow-up CT and MRI studies over 10 years that demonstrates the natural course and behavior of renal adenomatosis. Awareness of the imaging features on CT and MRI might help radiologists diagnose renal adenomatosis before surgery.

Abbreviations

MRI: Magnetic resonance imaging; CT: Computed tomography; CK7: Cytokeratin 7; AMACR: α-Methylacyl-coenzyme A racemase; T1W: T1-weighted; T2W: T2-weighted; ADC: Apparent diffusion coefficient; DWI: Diffusion-weighted image; FDG: Fluorodeoxyglucose; IgG4: Immunoglobulin G4; WHO: World Health Organization.

Acknowledgements

Not applicable.

Author contributions

YC drafted the manuscript. WL reviewed the pathologic specimens. SKH performed the operation. RW performed ultrasound-guided renal biopsy. YK edited the manuscript. All authors have read and approved the manuscript.

Funding

There is no funding for this study.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

The Ethics Committee of Chi Mei Medical Center approved this study (application no. 10905-E01).

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Medical Imaging, Chi Mei Medical Center, 901, Chung-Hwa Road, Yung-Kang, Tainan 710, Taiwan. 2Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan. 3Department of Pathology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 4Department of Radiology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 5Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 6Department of Radiology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Received: 21 December 2021 Accepted: 30 March 2022

Published online: 22 April 2022

References

1. Moch H, Humphrey P, Ulbright T, Reuter V. World health organization classification of tumors. Pathology and genetics of the urinary system and male genital organs. 4th edn; 2016.
2. Syrjanen KJ. Renal adenomatosis. Report of an autopsy case. Scand J Urol Nephrol. 1979;13:329–34.

3. Calio A, Warfel KA, Eble JN. Papillary adenomas and other small epithelial tumors in the kidney: an autopsy study. Am J Surg Pathol. 2019;43:277–87.

4. Fukuoka H, Goto A, Kitamura H. Renal adenomatosis associated with bilateral renal calculi. Nihon Jinzo Gakkai Shi. 1986;28:1293–8.

5. Spence GM, Hirschowitz L, Gallegos CR. Renal adenomatosis and unilateral hydronephrosis. BJU Int. 1999;84:380–1.

6. Kiyoshima K, Oda Y, Nakamura T, Migita T, Okumura K, Naito S, et al. Multicentric papillary renal cell carcinoma associated with renal adenomatosis. Pathol Int. 2004;54:266–72.

7. Wang KL, Weinrich DM, Luan C, Han M, Lin F, Teh BT, et al. Renal papillary adenoma—a putative precursor of papillary renal cell carcinoma. Hum Pathol. 2007;38:239–46.

8. Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol. 2003;16:1033–9.

9. Kim JY. Oncocytic papillary renal cell carcinoma in the background of renal adenomatosis. Int J Surg Pathol. 2017;25:78–82.

10. Kansal S, Chopra P, Dhawan S. AMACR positive papillary renal adenomatosis and multifocal papillary carcinoma in end stage renal disease. Indian J Surg Oncol. 2018;9:247–50.

11. Umbreit EC, Thompson RH. Metastatic potential of the small renal mass: why can’t we agree? Eur Urol. 2011;60:983–5; discussion 5–6.

12. Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009;182:41–5.

13. Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the kidney. J Am Soc Nephrol. 2001;12:1307–14.

14. Sankhe A, Joshi AR. Multidetector CT in renal tuberculosis. Curr Radiol Rep. 2014;2:69.

15. Sheth S, Ali S, Fishman E. Imaging of renal lymphoma: patterns of disease with pathologic correlation. Radiographics. 2006;26:1151–1158.

16. Meters U, Goor O, Lerman M, Naparstek E, Even-Sapir E. PET-CT of extranodal lymphoma. AJR Am J Roentgenol. 2004;182:1579–1586.

17. Seo N, Kim JH, Byun JH, Lee SS, Kim HJ, Lee MG. Immunoglobulin G4-related kidney disease: a comprehensive pictorial review of the imaging spectrum, mimickers, and clinicopathological characteristics. Korean J Radiol. 2015;16:1056–1067.

18. Martinez-de-Alegria A, Baleato-Gonzalez S, Garcia-Figueiras R, Bermudez-Naveira A, Abdulkader-Nallib I, Diaz-Perezmingo JA, et al. IgG4-related disease from head to toe. Radiographics. 2015;35:2007–2017.

19. Takahashi N, Kawashima A, Fletcher JG, Chari ST. Renal involvement in patients with autoimmune pancreatitis: CT and MR imaging findings. Radiology. 2007;242:791–801.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.